{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:48:09Z","timestamp":1778802489726,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clon.2025.103788","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T22:04:36Z","timestamp":1739311476000},"page":"103788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Contemporary Long-term Survival Outcomes and Prognostic Factors in Adult grade 4 Astrocytoma: An Institutional Analysis"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5549-9867","authenticated-orcid":false,"given":"K.","family":"Narang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kataria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.S.","family":"Bisht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mayank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Shishak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Kaliyaperumal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tamilselvan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Kamaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clon.2025.103788_bib1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"6","key":"10.1016\/j.clon.2025.103788_bib2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"10","key":"10.1016\/j.clon.2025.103788_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.clon.2025.103788_bib4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clon.2025.103788_bib5","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A\u00a0randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.clon.2025.103788_bib6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.clon.2025.103788_bib7","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance Therapy with Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.clon.2025.103788_bib8","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.clon.2025.103788_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.clon.2025.103788_bib10","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002583","article-title":"Isocitrate Dehydrogenase (IDH) 1\/2 Mutations as Prognostic Markers in Patients with Glioblastomas","volume":"95","author":"Chen","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.clon.2025.103788_bib11","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.clon.2025.103788_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1215\/S1152851703000620","article-title":"Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis","volume":"6","author":"Lamborn","year":"2004","journal-title":"Neuro-oncol."},{"issue":"3","key":"10.1016\/j.clon.2025.103788_bib13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ijrobp.2010.06.012","article-title":"Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma","volume":"81","author":"Li","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.clon.2025.103788_bib14","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jamaoncol.2016.1373","article-title":"Association of the Extent of Resection with Survival in Glioblastoma: A Systematic Review and Meta-analysis","volume":"2","author":"Brown","year":"2016","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.clon.2025.103788_bib15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ijrobp.2021.05.001","article-title":"Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials","volume":"111","author":"Singh","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2025.103788_bib16","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1200\/JCO.2015.62.6606","article-title":"International Atomic Energy Agency Randomized Phase III Study of radiation therapy in elderly and\/or frail patients with newly diagnosed glioblastoma multiforme","volume":"33","author":"Roa","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.clon.2025.103788_bib17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijrobp.2016.11.006","article-title":"A\u00a0Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy with Concurrent and Adjuvant Temozolomide for Patients with Glioblastoma","volume":"97","author":"Shenouda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2025.103788_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2019.105573","article-title":"Intensity-modulated radiotherapy, coplanar volumetric-modulated arc, therapy, and noncoplanar volumetric-modulated arc therapy in, glioblastoma: A dosimetric comparison","volume":"187","author":"Hou","year":"2019","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.clon.2025.103788_bib19","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12885-016-2399-6","volume":"16","author":"Navarria","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clon.2025.103788_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/neuonc\/nos273","article-title":"Standards of care for treatment of recurrent glioblastoma--are we there yet?","volume":"15","author":"Weller","year":"2013","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.clon.2025.103788_bib21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.clon.2025.103788_bib22","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.3390\/biomedicines10081927","article-title":"Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era","volume":"10","author":"Leone","year":"2022","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.clon.2025.103788_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.clon.2025.103788_bib24","unstructured":"RTOG 0825: Phase III double-blind placebo-controlled trial of conventional concurrent chemoradiation and adjuvant temozolomide plus bevacizumab versus conventional concurrent chemoradiation and adjuvant temozolomide in patients with newly diagnosed glioblastoma. https:\/\/irochouston.mdanderson.org\/RPC\/CREDENTIALING\/files\/0825.pdf."},{"issue":"1","key":"10.1016\/j.clon.2025.103788_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.radonc.2015.12.003","article-title":"ESTRO-ACROP guideline \"target delineation of glioblastomas\"","volume":"118","author":"Niyazi","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2025.103788_bib26","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/neuonc\/not114","article-title":"Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: A randomized, double-blind, placebo-controlled trial","volume":"15","author":"Brown","year":"2013","journal-title":"Neuro-Oncol"},{"issue":"4","key":"10.1016\/j.clon.2025.103788_bib27","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3390\/molecules14041561","article-title":"Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article","volume":"14","author":"Koukourakis","year":"2009","journal-title":"Molecules"},{"key":"10.1016\/j.clon.2025.103788_bib28","unstructured":"Common terminology criteria for adverse events (CTCAE) version 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf [November 27, 2017]."},{"issue":"11","key":"10.1016\/j.clon.2025.103788_bib29","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.clon.2025.103788_bib30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","article-title":"Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"7","key":"10.1016\/j.clon.2025.103788_bib31","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3174\/ajnr.A3876","article-title":"Differentiation of tumor progression from pseudoprogression in patients with posttreatment glioblastoma using multiparametric histogram analysis","volume":"35","author":"Cha","year":"2014","journal-title":"AJNR Am J Neuroradiol"},{"issue":"2","key":"10.1016\/j.clon.2025.103788_bib32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/biomedicines10020285","article-title":"Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review","volume":"10","author":"Sidibe","year":"2022","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.clon.2025.103788_bib33","first-page":"XC04","article-title":"Comparative Study of Adjuvant Temozolomide Six Cycles Versus Extended 12 Cycles in Newly Diagnosed Glioblastoma Multiforme","volume":"11","author":"Bhandari","year":"2017","journal-title":"J\u00a0Clin Diagn Res"},{"issue":"3","key":"10.1016\/j.clon.2025.103788_bib34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/neuonc\/nop030","article-title":"Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma","volume":"12","author":"Kong","year":"2010","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.clon.2025.103788_bib35","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/j.clon.2023.01.012","article-title":"Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study","volume":"35","author":"Bosio","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"10.1016\/j.clon.2025.103788_bib36","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s12885-023-11043-6","article-title":"Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map","volume":"23","author":"Fu","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clon.2025.103788_bib37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13014-021-01767-9","article-title":"Current status and recent advances in reirradiation of glioblastoma","volume":"16","author":"Minniti","year":"2021","journal-title":"Radiat Oncol"},{"issue":"7","key":"10.1016\/j.clon.2025.103788_bib38","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/neuonc\/noad038","article-title":"Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults","volume":"25","author":"Weller","year":"2023","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.clon.2025.103788_bib39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11864-019-0641-6","article-title":"Treatment of Radiation-Induced Cognitive Decline in Adult Brain Tumor Patients","volume":"20","author":"Cramer","year":"2019","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"10.1016\/j.clon.2025.103788_bib40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12885-019-5317-x","article-title":"Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging","volume":"19","author":"Laprie","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2025.103788_bib41","article-title":"Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial)","volume":"7","author":"Laprie","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clon.2025.103788_bib42","doi-asserted-by":"crossref","unstructured":"Carrete LR, Young JS, Cha S. Advanced Imaging Techniques for Newly Diagnosed and Recurrent Gliomas. Front Neurosci. 16:787755. doi: 10.3389\/fnins.2022.787755.","DOI":"10.3389\/fnins.2022.787755"},{"issue":"4","key":"10.1016\/j.clon.2025.103788_bib43","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1227\/NEU.0000000000001202","article-title":"Imaging Surrogates of Infiltration Obtained Via Multiparametric Imaging Pattern Analysis Predict Subsequent Location of Recurrence of Glioblastoma","volume":"78","author":"Akbari","year":"2016","journal-title":"Neurosurgery"},{"issue":"5","key":"10.1016\/j.clon.2025.103788_bib44","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","article-title":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","volume":"7","author":"Stummer","year":"2006","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clon.2025.103788_bib45","first-page":"97","article-title":"Neuronavigation: principles, clinical applications, and potential pitfalls","volume":"7","author":"Khoshnevisan","year":"2012","journal-title":"Iran J Psychiatry"},{"issue":"4","key":"10.1016\/j.clon.2025.103788_bib46","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/neuonc\/noac198","article-title":"National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clon.2025.103788_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109663","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma","volume":"184","author":"Niyazi","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2025.103788_bib48","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11060-013-1326-9","article-title":"Raman spectroscopy to distinguish grey matter, necrosis, and glioblastoma multiforme in frozen tissue sections","volume":"116","author":"Kalkanis","year":"2014","journal-title":"J\u00a0Neuro Oncol"},{"issue":"5","key":"10.1016\/j.clon.2025.103788_bib49","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/cancers13051063","article-title":"Advanced Imaging Techniques for Radiotherapy Planning of Gliomas","volume":"13","author":"Castellano","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clon.2025.103788_bib50","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3389\/fonc.2019.00768","article-title":"Artificial Intelligence in the Management of Glioma: Era of Personalized Medicine","volume":"9","author":"Sotoudeh","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clon.2025.103788_bib51","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13046-022-02349-7","article-title":"Emerging therapies for glioblastoma:\u00a0current state and future directions","volume":"41","author":"Rong","year":"2022","journal-title":"J\u00a0Exp Clin Cancer Res"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655525000433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655525000433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T14:58:59Z","timestamp":1744297139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655525000433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":51,"alternative-id":["S0936655525000433"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2025.103788","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary Long-term Survival Outcomes and Prognostic Factors in Adult grade 4 Astrocytoma: An Institutional Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2025.103788","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103788"}}